Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology
Authors:
- 14 May 2026
- journal article
- consensus statement
- Published by Elsevier in Ophthalmology
- Vol. 133 (8) , 1029-1035
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 DiabetesJAMA Network Open, 2025
- GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 DiabetesJAMA Network Open, 2025
- Incretin Receptor Agonists and Nonarteritic Anterior Ischemic Optic Neuropathy and Other Ocular ComplicationsJAMA Network Open, 2025
- Association of Semaglutide and NAION ReviewedJAMA Ophthalmology, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With DiabetesJAMA Ophthalmology, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2025
- Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and TirzepatideJAMA Ophthalmology, 2025
- Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2024
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2024